The Greatest Prescription drugs for Youngsters Act (BPCA) and the Pediatric Analysis Equity Act (PREA) had been designed to encourage more pediatric studies of medication used for children. The FDA asked the IOM to evaluation facets of pediatric research and modifications in product labeling that resulted from BPCA and PREA and their predecessor insurance policies, in addition to assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these insurance policies have helped provide clinicians who care for kids with higher information about the efficacy, safety, and acceptable prescribing of drugs. The IOM means that more will be performed to increase data about medicine used by kids and thereby improve the scientific care, health, and effectively-being of the nation's children.
